Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats

Nasruddin E. El-Reyani, I. Baczkó, I. Leprán, J. Papp

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, on the development of myocardial infarction has been compared. Permanent coronary artery ligation was induced in rats and the development of infarction was evaluated by a computer-assisted method after nitroblue-terazolium staining. Seven-day coronary ligation produced enlargement of the left ventricular cavity, scar thinning and thickening of the non-infarcted myocardium. Glibenclamide treatment (5 mg/kg b.i.d, intraperitoneally) decreased the infarct volume (29.1±3.5% vs. 39.1±3.2% in controls), that occurred primarily as a result of more significant thinning of the scar tissue (1.6±0.04 mm vs. 2.0 ±0.13 mm in controls). Glibenclamide also inhibited the thickening of the non-infarcted ventricular septum (2.1±0.10 mm vs. 2.9±0.10 mm in controls). In contrast to the effects of glibenclamide, glimepiride treatment (5 mg/kg b.i.d, intraperitoneally) inhibited the enlargement of the left ventricular cavity (15.2±.1% vs. 19.9±1.2% of the left ventricular volume in controls), it did not precipitate scar thinning and did not influence the development of hypertrophy of the non-infarcted myocardium. These results suggest that glimepiride treatment might inhibit the development of left ventricular dilatation after myocardial infarction. Glibenclamide treatment, however, producing a thinning of the scar tissue may further precipitate morphological changes that can contribute to the development of heart failure.

Original languageEnglish
Pages (from-to)173-184
Number of pages12
JournalActa Physiologica Hungarica
Volume87
Issue number2
Publication statusPublished - 2000

Fingerprint

glimepiride
Glyburide
Myocardial Infarction
Cicatrix
Ligation
Myocardium
Ventricular Septum
Hypoglycemic Agents
Infarction
Hypertrophy
Dilatation
Coronary Vessels
Heart Failure
Staining and Labeling

Keywords

  • Glibenclamide
  • Glimepiride
  • Myocardial infarct size
  • Rat

ASJC Scopus subject areas

  • Physiology

Cite this

Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats. / El-Reyani, Nasruddin E.; Baczkó, I.; Leprán, I.; Papp, J.

In: Acta Physiologica Hungarica, Vol. 87, No. 2, 2000, p. 173-184.

Research output: Contribution to journalArticle

@article{59ffd9edac344213a7714ae487b472f9,
title = "Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats",
abstract = "The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, on the development of myocardial infarction has been compared. Permanent coronary artery ligation was induced in rats and the development of infarction was evaluated by a computer-assisted method after nitroblue-terazolium staining. Seven-day coronary ligation produced enlargement of the left ventricular cavity, scar thinning and thickening of the non-infarcted myocardium. Glibenclamide treatment (5 mg/kg b.i.d, intraperitoneally) decreased the infarct volume (29.1±3.5{\%} vs. 39.1±3.2{\%} in controls), that occurred primarily as a result of more significant thinning of the scar tissue (1.6±0.04 mm vs. 2.0 ±0.13 mm in controls). Glibenclamide also inhibited the thickening of the non-infarcted ventricular septum (2.1±0.10 mm vs. 2.9±0.10 mm in controls). In contrast to the effects of glibenclamide, glimepiride treatment (5 mg/kg b.i.d, intraperitoneally) inhibited the enlargement of the left ventricular cavity (15.2±.1{\%} vs. 19.9±1.2{\%} of the left ventricular volume in controls), it did not precipitate scar thinning and did not influence the development of hypertrophy of the non-infarcted myocardium. These results suggest that glimepiride treatment might inhibit the development of left ventricular dilatation after myocardial infarction. Glibenclamide treatment, however, producing a thinning of the scar tissue may further precipitate morphological changes that can contribute to the development of heart failure.",
keywords = "Glibenclamide, Glimepiride, Myocardial infarct size, Rat",
author = "El-Reyani, {Nasruddin E.} and I. Baczk{\'o} and I. Lepr{\'a}n and J. Papp",
year = "2000",
language = "English",
volume = "87",
pages = "173--184",
journal = "Physiology International",
issn = "2498-602X",
publisher = "Akademiai Kiado",
number = "2",

}

TY - JOUR

T1 - Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats

AU - El-Reyani, Nasruddin E.

AU - Baczkó, I.

AU - Leprán, I.

AU - Papp, J.

PY - 2000

Y1 - 2000

N2 - The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, on the development of myocardial infarction has been compared. Permanent coronary artery ligation was induced in rats and the development of infarction was evaluated by a computer-assisted method after nitroblue-terazolium staining. Seven-day coronary ligation produced enlargement of the left ventricular cavity, scar thinning and thickening of the non-infarcted myocardium. Glibenclamide treatment (5 mg/kg b.i.d, intraperitoneally) decreased the infarct volume (29.1±3.5% vs. 39.1±3.2% in controls), that occurred primarily as a result of more significant thinning of the scar tissue (1.6±0.04 mm vs. 2.0 ±0.13 mm in controls). Glibenclamide also inhibited the thickening of the non-infarcted ventricular septum (2.1±0.10 mm vs. 2.9±0.10 mm in controls). In contrast to the effects of glibenclamide, glimepiride treatment (5 mg/kg b.i.d, intraperitoneally) inhibited the enlargement of the left ventricular cavity (15.2±.1% vs. 19.9±1.2% of the left ventricular volume in controls), it did not precipitate scar thinning and did not influence the development of hypertrophy of the non-infarcted myocardium. These results suggest that glimepiride treatment might inhibit the development of left ventricular dilatation after myocardial infarction. Glibenclamide treatment, however, producing a thinning of the scar tissue may further precipitate morphological changes that can contribute to the development of heart failure.

AB - The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, on the development of myocardial infarction has been compared. Permanent coronary artery ligation was induced in rats and the development of infarction was evaluated by a computer-assisted method after nitroblue-terazolium staining. Seven-day coronary ligation produced enlargement of the left ventricular cavity, scar thinning and thickening of the non-infarcted myocardium. Glibenclamide treatment (5 mg/kg b.i.d, intraperitoneally) decreased the infarct volume (29.1±3.5% vs. 39.1±3.2% in controls), that occurred primarily as a result of more significant thinning of the scar tissue (1.6±0.04 mm vs. 2.0 ±0.13 mm in controls). Glibenclamide also inhibited the thickening of the non-infarcted ventricular septum (2.1±0.10 mm vs. 2.9±0.10 mm in controls). In contrast to the effects of glibenclamide, glimepiride treatment (5 mg/kg b.i.d, intraperitoneally) inhibited the enlargement of the left ventricular cavity (15.2±.1% vs. 19.9±1.2% of the left ventricular volume in controls), it did not precipitate scar thinning and did not influence the development of hypertrophy of the non-infarcted myocardium. These results suggest that glimepiride treatment might inhibit the development of left ventricular dilatation after myocardial infarction. Glibenclamide treatment, however, producing a thinning of the scar tissue may further precipitate morphological changes that can contribute to the development of heart failure.

KW - Glibenclamide

KW - Glimepiride

KW - Myocardial infarct size

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=0034494511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034494511&partnerID=8YFLogxK

M3 - Article

C2 - 11205966

AN - SCOPUS:0034494511

VL - 87

SP - 173

EP - 184

JO - Physiology International

JF - Physiology International

SN - 2498-602X

IS - 2

ER -